

Paul Lee



PTH-Vitamin D-Glycemia Interactions Reloaded



Diabetes 2014;63:3593–3595 | DOI: 10.2337/db14-0956

Traditionally viewed as a key regulator of musculoskeletal health, recent studies also have pointed to pleiotropic roles of vitamin D in the modulation of metabolic and vascular functions (1). Hypovitaminosis D is associated with obesity (2), and low vitamin D states predict higher fasting glycemia and insulin resistance in population studies (3,4), yet other studies showed no relations between vitamin D status and glucose homeostasis after adjusting for adiposity (5,6). Vitamin D supplementation has not consistently benefited glycemia in intervention trials despite adequate increments into a “normal range” (7). The debate surrounding vitamin D and glucose metabolism continues. Aside from assay variability, subject population, and lifestyle confounders that could complicate data interpretation, a fundamental unanswered question is what constitutes vitamin D sufficiency.

Hormonal axes are classically evaluated on multiple levels, encompassing negative feedback and positive stimulation. The vitamin D hormonal system is chiefly under the regulation of the parathyroid hormone (PTH), which stimulates the conversion of circulating 25-hydroxyvitamin D (25-OH-D) to its active form, 1,25-dihydroxyvitamin D (1,25-(OH)₂D). While best known to occur in the kidneys, local tissue 1 α -hydroxylase expression enables active vitamin D synthesis in a paracrine fashion (1). The interactions between endocrine and paracrine vitamin D systems are not well understood and may underscore the apparent dissociation between PTH and 25-OH-D levels in some clinical settings. For example, PTH responsiveness may determine the outcome among vitamin D–insufficient/deficient critically ill patients (8). In other words, PTH may be normal or elevated to different extents in patients with comparable 25-OH-D circulating status. Higher PTH response correlates with excess mortality in the elderly (9). Whether higher PTH is causal to morbidity and mortality; reflects more profound vitamin D deficiency, such as tissue-level deficiency (10); or is a biomarker of other yet-to-be defined secondary factors is not known.

These possibilities have prompted the inclusion of PTH measurements in clinical investigations of vitamin D status in patients with dysmetabolism (11).

In this issue, Kramer et al. (12) tackled this conundrum within the context of vitamin D deficiency, parathyroid status, and insulin sensitivity changes postpartum. By prospectively evaluating predictors for evolution of β -cell function and insulin sensitivity, the authors identified vitamin D–deficient/insufficient states in conjunction with higher PTH levels (upper third tertiles but within normal range) 3 months postpartum, but not either alone, to be an independent predictor of worse glycemia, β -cell function, and insulin sensitivity 9 months later. Close to one-third of the participants with vitamin deficiency and third tertile PTH developed prediabetes/diabetes at 12 months postpartum. These results are provocative and shed novel insight on multiple clinical and mechanistic levels.

First, combined vitamin D and PTH status assessment has unveiled a state of functional vitamin D deficiency relevant to glucose homeostasis, not apparent by either alone. Greater PTH elevation among those with low circulating 25-OH-D levels could signify more severe vitamin D deficiency. Recognizing the aforementioned limitation of absolute 25-OH-D level in differentiating paracrine versus endocrine active vitamin D derivation, it is tempting to speculate that higher PTH levels reflect target tissue-level deficiency. Based on vitamin D action in the pancreas and other insulin-responsive end organs, tissue vitamin D deficiency could explain the observed worsening β -cell function and insulin sensitivity over time. In contrast, low circulating vitamin D level alone, without a rise of PTH into the upper third tertile, could be interpreted as adequate tissue active vitamin D derivation, rather than true deficiency per se.

Second, as adipose tissue is a major storage site of vitamin D, fat mass could impact both vitamin D and PTH levels. Intriguingly, the predictive power of low vitamin D/high PTH state was independent of baseline adiposity




Figure 1—Putative dysglycemic mechanisms underlying vitamin D deficiency postpartum characterized by “heightened” PTH response as a result of 1) more severe tissue level vitamin D deficiency, 2) mineral and/or renal insufficiency, and 3) bone-derived PTH-responsive insulin-sensitizing/antagonizing factors and cytokines. BMPs, bone morphogenetic proteins; FGF23, fibroblast growth factor 23; Vit D def., vitamin D deficiency.

and changes over the 9-month follow-up period. This implies a primary effect of PTH-vitamin D axis on glycemia, beyond the well-known adipose-driven impact.

Third, relative excess risk of dysglycemia and insulin resistance among women with combined vitamin D deficiency/third tertile PTH response exceeded either states in isolation, thus raising the question of whether other additional factors could be contributing. Kramer et al. did not examine for factors of secondary PTH rise, such as low calcium intake, hypomagnesemia, and/or renal insufficiency. Given known associations of all these conditions with worse β -cell function and insulin resistance (13–15), one could not exclude the possibility that the observed higher PTH state may harbor other overt dysglycemic factors. Furthermore, bone–pancreas cross talk is a newly recognized endocrine modulator of glucose homeostasis (16). Osteocalcin is a bone factor with direct stimulatory effects on β -cell function (17). As PTH is linked to higher bone resorption, common in the postpartum period, future studies should investigate whether heightened PTH secretion impacts bone turnover, thereby imparting adverse glycemic effects.

The longitudinal follow-up is a notable strength of the study; however, results obtained in the postpartum period may not be generalizable to other populations. Calcitropic hormones undergo significant changes throughout pregnancy (18). Calcitriol initially rises while PTH falls; after delivery, PTH increases to above prepregnancy levels and has been interpreted as a secondary response to relative calcium deficiency from lactation. Whether the adverse glycemic sequelae predicted by the low vitamin D/third tertile PTH state within the unique postpartum calcitropic hormonal milieu translates to other populations is unclear.

In addition to pinpointing the pivotal importance of PTH status in determining the impact of vitamin D deficiency on glucose and insulin metabolism, the study by Kramer

et al. (12) illuminates the complex interplay among the myriad of calcitropic and glucose homeostatic hormones (Fig. 1). It is time to think beyond the realms of traditional liver-muscle-pancreas-adipose tetrad and consider other facets of the metabolic world. It is possible that PTH status is only one piece of the vitamin D-glucose-insulin puzzle, and other players, such as the newly discovered fibroblast growth factor 23 (19) and bone morphogenetic proteins (20), also could exert modulatory effects on individuals with given vitamin D and PTH status.

Funding. P.L. was supported by an Australian National Health and Medical Research Council Early Career Fellowship and a Diabetes Australia Research Trust Grant from Diabetes Australia.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

References

1. Bikle D. Nonclassic actions of vitamin D. *J Clin Endocrinol Metab* 2009;94:26–34
2. Lee P, Greenfield JR, Seibel MJ, Eisman JA, Center JR. Adequacy of vitamin D replacement in severe deficiency is dependent on body mass index. *Am J Med* 2009;122:1056–1060
3. Gagnon C, Lu ZX, Magliano DJ, et al. Serum 25-hydroxyvitamin D, calcium intake, and risk of type 2 diabetes after 5 years: results from a national, population-based prospective study (The Australian Diabetes, Obesity and Lifestyle Study). *Diabetes Care* 2011;34:1133–1138
4. Gagnon C, Lu ZX, Magliano DJ, et al. Low serum 25-hydroxyvitamin D is associated with increased risk of the development of the metabolic syndrome at five years: results from a national, population-based prospective study (The Australian Diabetes, Obesity and Lifestyle Study: AusDiab). *J Clin Endocrinol Metab* 2012;97:1953–1961
5. Rajakumar K, de las Heras J, Lee S, Holick MF, Arslanian SA. 25-Hydroxyvitamin D concentrations and in vivo insulin sensitivity and β -cell function relative to insulin sensitivity in black and white youth. *Diabetes Care* 2012;35:627–633
6. Muscogiuri G, Sorice GP, Prioletta A, et al. 25-Hydroxyvitamin D concentration correlates with insulin-sensitivity and BMI in obesity. *Obesity (Silver Spring)* 2010;18:1906–1910

7. George PS, Pearson ER, Witham MD. Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. *Diabet Med* 2012;29:e142–e150
8. Nair P, Lee P, Reynolds C, et al. Significant perturbation of vitamin D-parathyroid-calcium axis and adverse clinical outcomes in critically ill patients. *Intensive Care Med* 2013;39:267–274
9. Chen JS, Sambrook PN, March L, et al. Hypovitaminosis D and parathyroid hormone response in the elderly: effects on bone turnover and mortality. *Clin Endocrinol (Oxf)* 2008;68:290–298
10. Lee P. Vitamin D metabolism and deficiency in critical illness. *Best Pract Res Clin Endocrinol Metab* 2011;25:769–781
11. Stanley T, Bredella MA, Pierce L, Misra M. The ratio of parathyroid hormone to vitamin D is a determinant of cardiovascular risk and insulin sensitivity in adolescent girls. *Metab Syndr Relat Disord* 2013;11:56–62
12. Kramer CK, Swaminathan B, Hanley AJ, et al. Prospective associations of vitamin D status with β -cell function, insulin sensitivity, and glycemia: the impact of parathyroid hormone status. *Diabetes* 2014;63:3868–3879
13. Tosiello L. Hypomagnesemia and diabetes mellitus. A review of clinical implications. *Arch Intern Med* 1996;156:1143–1148
14. Pittas AG, Dawson-Hughes B, Li T, et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. *Diabetes Care* 2006;29:650–656
15. Fliser D, Pacini G, Engelleiter R, et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. *Kidney Int* 1998;53:1343–1347
16. Wei J, Ferron M, Clarke CJ, et al. Bone-specific insulin resistance disrupts whole-body glucose homeostasis via decreased osteocalcin activation. *J Clin Invest* 2014;124:1–13
17. Oury F, Ferron M, Huizhen W, et al. Osteocalcin regulates murine and human fertility through a pancreas-bone-testis axis. *J Clin Invest* 2013;123:2421–2433
18. Møller UK, Streyms S, Mosekilde L, et al. Changes in calcitropic hormones, bone markers and insulin-like growth factor I (IGF-I) during pregnancy and postpartum: a controlled cohort study. *Osteoporos Int* 2013;24:1307–1320
19. Wojcik M, Janus D, Dolezal-Oltarzewska K, Drozd D, Sztefko K, Starzyk JB. The association of FGF23 levels in obese adolescents with insulin sensitivity. *J Pediatr Endocrinol Metab* 2012;25:687–690
20. Böttcher Y, Unbehauen H, Klötting N, et al. Adipose tissue expression and genetic variants of the bone morphogenetic protein receptor 1A gene (BMPRI1A) are associated with human obesity. *Diabetes* 2009;58:2119–2128